Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...
In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that their work should heal and repair the wounds of racial difference as ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
JDK 25 brings powerful new features to Java and JVM developers. Here are seven new or updated features that could convince you to switch. Java continues its fast and feature-packed release schedule, ...
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Long-Term Support release, with features ranging from structured concurrency and compact object headers to ahead-of-time method profiling and JFR CPU-time profiling on Linux, is now generally ...
Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest topic on Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results